- Highlights included positive Phase 2b data with COMP360 from a ground-breaking treatment resistant depression (TRD) trial, highly encouraging Phase 2a proof-of-mechanism data with RL-007 in cognitive
Investegate announcements from atai Life Sciences, atai Life Sciences to Host Conference Call and Webcast to Discuss Results for the Fourth Quarter and Full Year 2021 and Corporate Update
atai Life Sciences to Host Conference Call and Webcast to Discuss Results for the Fourth Quarter and Full Year 2021 and Corporate UpdateNEW YORK and BERLIN, March 23, 2022 (GLOBE NEWSWIRE) atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform t.
NEW YORK, March 21, 2022 atai Life Sciences N.V. , a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the following. | March 21, 2022